^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Litfulo (ritlecitinib)

    i
    Other names: PF-06651600, PF-6651600, PF 6651600, PF 06651600, PF6651600
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    JAK3 inhibitor, TEC inhibitor
    Associations

    News

    Trials
    13d
    COMBIVIT: Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Centre Hospitalier Universitaire de Nice
    Trial initiation date
    |
    Litfulo (ritlecitinib)
    13d
    B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Recruiting, Pfizer | N=71 --> 240
    Enrollment change • Trial initiation date
    |
    Litfulo (ritlecitinib)
    14d
    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Litfulo (ritlecitinib)
    14d
    Tranquillo LTE: A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (clinicaltrials.gov)
    P3, N=394, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Litfulo (ritlecitinib)
    15d
    B7981028: A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. (clinicaltrials.gov)
    P3, N=140, Recruiting, Pfizer
    Trial initiation date
    |
    Litfulo (ritlecitinib)
    25d
    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission (clinicaltrials.gov)
    P2, N=62, Completed, Massachusetts General Hospital | Recruiting --> Completed | N=40 --> 62 | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date
    |
    Litfulo (ritlecitinib)
    29d
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Recruiting, Pfizer | N=46 --> 200
    Enrollment change • Trial initiation date
    |
    Litfulo (ritlecitinib)
    1m
    ALLEGRO-LT: Long-Term PF-06651600 for the Treatment of Alopecia Areata (clinicaltrials.gov)
    P3, N=1057, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    Litfulo (ritlecitinib)
    1m
    B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=71, Recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    1m
    COMBIVIT: Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo (clinicaltrials.gov)
    P2, N=56, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    1m
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=46, Recruiting, Pfizer | N=21 --> 46
    Enrollment change
    |
    Litfulo (ritlecitinib)
    1m
    B7981027: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata (clinicaltrials.gov)
    P3, N=225, Recruiting, Pfizer
    Trial initiation date
    |
    Litfulo (ritlecitinib)